Please assess the completion status of the following clinical trial:

Trial Title: VenaSeal Sapheon Closure System Pivotal Study (VeClose)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 21 years and ≤ 70 years of age at the time of screening~2. Reflux in the great saphenous vein (GSV) greater than 0.5 sec reflux~3. One or more of the following symptoms related to the target vein: aching, throbbing, heaviness, fatigue, pruritis, night cramps, restlessness, generalized pain or discomfort, swelling~4. GSV diameter while standing of 3-12 mm throughout the target vein as measured by Duplex ultrasound~5. Clinical, etiology, assessment and pathophysiology (CEAP) classification of C2 (if symptomatic) - C4b~6. Ability to walk unassisted~7. Ability to attend follow-up visits~8. Ability to understand the requirements of the study and to provide informed consent~Exclusion Criteria:~1. Life expectancy \< 1 year~2. Active treatment for malignancy other than non-melanoma skin cancer~3. Symptomatic peripheral arterial disease with ankle-brachial index (ABI) \<0.89~4. Daily use of narcotic or non-steroidal anti-inflammatory pain medications to control pain associated with GSV reflux~5. Current, regular use of systemic anticoagulation (e.g., warfarin, heparin)~6. Previous or suspected deep vein thrombosis (DVT) or pulmonary embolus (PE)~7. Previous superficial thrombophlebitis in GSV~8. Previous treatment of venous disease in target limb, other than spider vein treatment~9. Known hypercoagulable disorder~10. Conditions which prevent vein treatment with either RFA or VenaSeal SCS~11. Immobilization or inability to ambulate~12. Pregnant prior to enrollment~13. Tortuous GSV, which, in the opinion of the investigator, will limit catheter placement or require more than one primary access site~14. Aneurysm of the target vein with local diameter \>12 mm~15. Significant, incompetent, ipsilateral small saphenous, intersaphenous or anterior accessory great saphenous vein(s)~16. Known sensitivity to cyanoacrylate (CA) adhesives~17. Current participation in another clinical study involving an investigational agent or treatment, or within the 30 days prior to enrollment~18. Patients who require bilateral treatment during the next 3 months~19. Patients who require additional ipsilateral treatments on the same leg within 3 months following treatment

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- VenaSeal SCS (Type: EXPERIMENTAL): Endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV). The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc. Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or to RFA.
- RFA (ClosureFast) (Type: ACTIVE_COMPARATOR): Endovenous insertion of the ClosureFast radiofrequency ablation (RFA) catheter into a target site in diseased great saphenous veins (GSV). Heat is applied to the target vein using radiofrequency energy to ablate the target vein. Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or RFA.
- Roll-in (VenaSeal SCS) (Type: EXPERIMENTAL): Prior to initiation of the randomized cohort at each site, a non-randomized cohort of 2 subjects per clinical site (roll-in phase) were enrolled and treated with VenalSeal SCS with endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV). The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc.

Based on this trial design, predict the completion outcome and termination type (if applicable).